Search
EN Down
Language
Hi, user_no_name
Live Chat

Moderna Share Price

 

Moderna share price rockets higher after Oppenheimer upgrades stock 

 
Moderna shares soared over 13% on Tuesday and extended their gains into Wednesday following an "outperform" rating from the investment bank Oppenheimer, which suggested the Covid vaccine producer could introduce five new products to the market by 2026. 

Despite a challenging 2023, marked by a substantial decline in demand for Covid-related products, Moderna's stock saw a significant boost with Oppenheimer's upgrade. The pharmaceutical company, heavily reliant on its Covid shot, witnessed a nearly 45% drop in its share price last year. 

Moderna rivals such have also suffered from similar factors. The Pfizer share price fell by over 40% over the past year, while BioNTech stock shed over 24.5% of its value and AstraZeneca shares declined by over 7%. Pfizer stock took its latest hit in December, when the New York-based pharma company projected 2024 revenue and profit below Wall Street's expectations due to lower Covid-related revenues. 

Oppenheimer analyst Hartaj Singh acknowledged the potential for a dip in Covid sales for Moderna in 2024 due to factors like vaccine fatigue. However, the firm anticipates a resurgence in Covid vaccine sales in 2025 and beyond, fueled by increased awareness and education about the disease. 

Singh expressed optimism about Moderna's pipeline, pointing to potential product launches in the next 12 to 18 months that could drive sales in 2025. This includes the potential approval of Moderna's experimental vaccine targeting respiratory syncytial virus (RSV) in older adults. A decision from the U.S. Food and Drug Administration (FDA) is expected in April. 

 

Choose your points of movement

Сalculate your hypothetical P/L (aggregated cost and charges) if you had opened a trade today.

Market

Shares Search
Shares
Index
Commodity
Bonds
Crypto
ETFs
Currency

Instrument

Search
Clear input
Occidental
Prosus N.V.
Porsche AG
Hermes
CAT
Thermo Fisher
Nikola Corporation
Tilray
Shell plc (LSE)
Skillz Inc
Iberdrola
DeltaAir
CrowdStrike Holdings
Golar LNG
Applied Materials
Snowflake
Royal Bank Canada
Amazon.com
Spotify
Exxon Mobil
CCB (Asia)
McDonald's
Campari
GameStop
Netflix
ON Semiconductor
Costco
Dave & Buster's
Delivery Hero SE
LUCID
Continental
SunPower
Zoom Video Communications
Schlumberger
Virgin Galactic
Upwork Inc.
Cameco
JP Morgan
Fuelcell
Rivian Automotive
XPeng Inc
Wal-Mart Stores
Trade Desk
Blackstone
Vodafone
Aptiv PLC
L'Oreal
Target
Rio Tinto
Sartorius AG
British American Tobacco
Qorvo
ASOS
Cisco Systems
Nel ASA
Arista
Airbus
Apple
Pfizer
AMC Entertainment Holdings
ASML
Hubspot
Teladoc
Starbucks
SMCI
Canopy Growth
Wish.com Inc
Lockheed Martin
ProSiebenSat.1
IAG
AbbVie
Marston's
Baidu
Teleperformance
Norwegian Air Shuttle
Airbus Group SE
HSBC HK
Block
Annaly Capital
Abbott
LVMH
American Express
Novavax
GoPro
Siemens
Total
SIG
Pinterest Inc
Taiwan Semi
Etsy
Amgen
SONY
3D Systems
UPS
Yandex
BlackBerry
Gen Digital Inc
Xiaomi
Quanta Services
Unity Software
NVIDIA
Anglo American
Palantir Technologies Inc
Fresnillo
Deere
Rolls-Royce
Porsche
Uber
Vir Biotechnology
American Airlines
ROBLOX Corp
Macy's
FirstRand
easyJet
DISNEY
Aurora Cannabis Inc
BP
Adidas
Boeing Co
Vonovia
Coca-Cola Co (NYSE)
Home Depot
General Electric
Coinbase Inc
ALIBABA HK
Philip Morris
General Motors
PayPal
UniCredit
II-VI
BASF
Kraft Heinz
Alphabet (Google)
Palo Alto Networks
Evraz
Plug Power
Li Auto
Oracle
Roku Inc
UiPath Inc
Upstart Holdings Inc
F5 Networks
Infinera
Inditex
ZIM Integrated Shipping Services Ltd
Deutsche Bank
Hammerson
IBM
JD.com
Barrick Gold
TUI AG (LSE)
Lemonade
MerckCo USA
Infosys
Invesco Mortgage
Comcast
Santander
Accenture
Anheuser-Busch Inbev
Visa
Mastercard
Ozon
T-Mobile
SAP
Wayfair
Beyond Meat
Kuaishou
CarMax
Tesla
Lyft
Medtronic
Adobe
Morgan Stanley
Workday Inc
Blackrock
Vipshop
Meta (Formerly Facebook)
Linde PLC
Micron
Lululemon
Ceconomy
Chipotle
Gilead
Avacta
Naspers
Bristol Myers
Samsung
The Cheesecake Factory
Glencore plc
British American Tobacco
ChargePoint Holdings Inc
Twilio
Intel
Lloyds
CNOOC
Electrolux
Wells Fargo
Sea
PG&E
Fedex
Citigroup
Peloton Interactive Inc.
eBay
Microsoft
JnJ
Bilibili Inc
Trump Media & Technology Group
AIA
Nasdaq
Air France-KLM
Allianz
Lithium Americas Corp
Procter & Gamble
Qualcomm
AMD
New Oriental
MercadoLibre.com
Mondelez
Lumentum Holdings
Two Harbors Investment aration
AstraZeneca
Norwegian Cruise Line
Unilever
GoHealth
PepsiCo
Barclays
PETROCHINA
Goldman Sachs
Eli Lilly
HSBC
Cellnex
Berkshire Hathaway
Jumia Technologies
HDFC Bank
RTX Corp
Bayer
Bank of America
Chevron
ADT
DoorDash
Marriott
Nike
AT&T
GSX Techedu
Robinhood
Telecom Italia
Deliveroo Holdings
TUI
Freeport McMoRan
Toyota
BioNTech
Airbnb Inc
Alibaba
Verizon
Nio
Eni
Ford
Hanesbrands
Volkswagen
UnitedHealth
Shopify
China Life
Snap
Christian Dior
Conoco Phillips
Lufthansa
Tencent
Moderna Inc
Salesforce.com
Broadcom
Diageo
Toro
Cinemark

Account Type

Direction

Quantity

Amount must be equal or higher than

Amount should be less than

Amount should be a multiple of the minimum lots increment

USD Down
$-

Value

$-

Commission

$-

Spread

-

Leverage

-

Conversion Fee

$-

Required Margin

$-

Overnight Swaps

$-
Start Trading

Past performance is not a reliable indicator of future results.

All positions on instruments denominated in a currency that is different from your account currency, will be subject to a conversion fee at the position exit as well.

 

Moderna share price: New vaccines may provide support for the Covid-19 shot maker’s stock, says Oppenheimer 

Singh also highlighted the possibility of FDA approval for Moderna's experimental flu vaccine in 2024 or 2025. Recent trial results indicated a stronger immune response against four flu virus strains compared to currently available vaccines. 

The analyst suggested that Moderna also might seek FDA approval for its experimental personalized cancer vaccine in 2024 or 2025. The company could utilize the FDA's accelerated approval pathway, expediting the process for drugs addressing serious conditions with an unmet medical need, based on specific clinical trial metrics. 

Moderna and its partner, pharma multinational Merck, are currently conducting studies on the cancer vaccine in conjunction with Merck's Keytruda therapy, targeting patients with melanoma and other cancers. 

On Tuesday, Moderna reiterated its anticipation of sales growth in 2025, as outlined in a shareholder letter. The company emphasized the potential approval of its RSV vaccine and a combination shot targeting both Covid and the flu, with the latter possibly receiving approval "as early as 2025." 

In its third-quarter earnings release last November, Moderna projected a decline in revenue to $4 billion in 2024 before expecting growth in 2025. The company aims to achieve a "break even" point in 2026. November's announcement also indicated that Moderna was likely to reach the lower end of its sales forecast range of $6 billion to $8 billion for 2023, reflecting diminished demand for Covid vaccines. 

Moderna has also expressed its intention to introduce up to 15 products in the next five years — a goal initially outlined during its annual research and development day in September. 

Moderna share price forecast: Majority of analysts bullish on MRNA stock 

According to 16 analysts surveyed by TipRanks that offered 12-month Moderna share price targets, the consensus forecast for MRNA stock stands at $134.07 — a potential 23.15% upside from its current price as of January 3, 2024. 

The highest listed Moderna stock price forecast on the platform is $310.00, while the lowest stands at $60. Of the 16 analysts surveyed, 8 offered a Buy rating on Moderna stock, while 6 had it as a Hold, and 2 gave it a Sell. 

At the time of writing on Wednesday, Moderna shares, which trade on the Nasdaq stock market under the ticker MRNA, were close to 3.60% down on the day at $108.41, after having closed up over 13% on Tuesday at $112.50.  

The MRNA share price was close to 38% down since January 3, 2023. 

When considering shares for trading and price predictions, remember that trading CFDs involves a significant degree of risk and could result in capital loss.  

Past performance is not indicative of any future results. This information is provided for informative purposes only and should not be construed to be investment advice. 

Latest news

UBS Global Research issues Street-high S&P 500 forecast

Tuesday, 28 May 2024

Indices

UBS leapfrogs UBS with new year-end S&P 500 forecast

Gold price gains ahead of US PCE inflation release

Monday, 27 May 2024

Indices

Gold price gains as focus turns to US inflation data

US dollar slated to remain firm over Memorial Day weekend

Friday, 24 May 2024

Indices

US dollar holds firm as traders trim Fed rate cut bets

OPEC meeting in focus for traders this week

Thursday, 23 May 2024

Indices

Week ahead: Oil traders eye next OPEC meeting, big inflation week

Live Chat